Leerink Partners analyst Jonathan Chang maintained a Hold rating on Adaptimmune Therapeutics (ADAP) today and set a price target of $6.00. The company’s shares closed last Thursday at $5.35.
According to TipRanks.com, Chang is a 5-star analyst with an average return of 25.5% and a 56.3% success rate. Chang covers the Healthcare sector, focusing on stocks such as Karyopharm Therapeutics, Five Prime Therapeutics, and Revolution Medicines.
Currently, the analyst consensus on Adaptimmune Therapeutics is a Moderate Buy with an average price target of $10.00, an 83.5% upside from current levels. In a report released today, Mizuho Securities also maintained a Hold rating on the stock with a $9.00 price target.
See today’s analyst top recommended stocks >>
Based on Adaptimmune Therapeutics’ latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $502K and GAAP net loss of $29.88 million. In comparison, last year the company earned revenue of $157K and had a GAAP net loss of $41.09 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Adaptimmune Therapeutics Plc engages in the development of novel cancer immunotherapy products. Its specific peptide enhanced affinity receptor platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom.
